Although the activation of Ras pathway is frequently observed in human hepatocellular carcinoma (HCC), the in vivo role of Ras activation in HCC initiation and progression is underdetermined. To test the consequence of Kras activation in hepatocyte, we generated a hepatocyte-specific Kras G12D transgenic mouse strain and observed spontaneous development of HCC in these mice. Remarkably, HBV X protein (HBx) expression significantly promotes the formation and malignant progression of Kras G12D -driven HCC as shown with the accelerated tumor onset, the increased tumor burden and the more poorly differentiated lesions. At the cellular level, concomitant expression of Kras G12D and HBx results in a robust increase in hepatocellular proliferation. We reveal that the Akt, MAPK, p53 and TGF-b pathways are deregulated in the Kras G12D -driven HCCs. Also, the dysregulation is more pronounced in the HCCs developed in Kras  G12D and HBx double transgenic mice. In addition, the altered expressions of b-catenin, CD44 and E-cadherin are only observed in the Kras G12D and HBx double transgenic mice. These results demonstrate a crucial role of Ras activation in hepatocellular carcinogenesis and the functional synergy between Kras G12D and HBx in HCC initiation and progression. The novel genetic mouse models that closely recapitulate the histopathologic progression and molecular alterations of human HCC may potentially facilitate the future therapeutic studies.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancer types worldwide. An estimated 748 300 new liver cancer cases and 695 900 cancer deaths occurred worldwide in 2008. 1 Among the primary liver cancers, HCC represents the major histological subtype, accounting for 70-85% of the total cases. 1 HCC results from a combination of environmental factors such as hepatitis B virus (HBV) infection and the accumulation of generalized and specific genetic alterations. 2, 3 Although mounting evidence indicates that the alterations of some pathways, such as p53, b-catenin and c-myc, can initiate HCC in mice, [4] [5] [6] the molecular pathogenesis of HCC is still under intense investigation.
Ras proteins, a family of small guanosine triphosphateregulated molecular switches, activate many downstream pathways that are key regulators of cellular proliferation, transformation and malignant progression. 7 The members of Ras family include Hras, Nras and Kras, each of which exerts the distinct cellular and molecular responses dependent on cell types. Kras mutations have been found in approximately 7% of human liver cancers, which are higher than that of Hras and Nras mutations. 8 More importantly, the activation of Ras signaling has been found in all examined human HCC, albeit with the presence of wild-type Ras gene in HCC tissues. 9 In vitro, Ras activation leads to hepatocellular proliferation and transformation. 10 However, neither Nras nor Hras mutation in mouse liver is sufficient to induce HCC. 11, 12 A recent study has reported that hepatocytespecific Kras mutation results in intrahepatic cholangiocarcinoma in mice, but not HCC. 13 Interestingly, a pancreatic-specific Kras mutation (Mist1-Kras G12D ) mouse strain displays HCC for unexplained reasons, since Mist1 does not express in embryonic or adult hepatic tissues.
14 Therefore, whether hepatocyte-specific Kras mutation can initiate HCC formation in mice remains unknown.
HBV infection is epidemiologically associated with the development of HCC. 15 Increasing evidence indicates that HBV genes exert direct hepatocarcinogenic effects. 16 Among the four proteins encoded by HBV, HBV X protein (HBx) is a multifunctional regulatory protein and essential for HBV-induced carcinogenesis. 17 HBx acts both as a transactivator to activate many key pathways 18, 19 and as a transcriptional factor that stimulates the expression of some proto-oncogenes, thereby controlling hepatocellular proliferation, transformation, apoptosis and DNA repair. 20 In our previous studies, we have generated a HBx transgenic mouse strain by introducing the HBx gene into p21 locus. 21 Approximately 60% of HBx gene knockin transgenic mice spontaneously developed HCC after 18 months of age. Mechanistically, a broad range of factors related to metabolism, genomic instability, oxidative stress and cellular cytoskeleton are dysregulated in HBx-induced HCC. [21] [22] [23] [24] In addition, the genetic alterations of certain genes, such as p53, c-myc and insulin receptor substrate-1, collaborate with HBx to promote HCC development in mice, 4, 5, 25 whereas no synergistic action between Nras mutation and HBx occurs in a mouse HCC model established by a sleeping beauty transposon system. 11 However,
whether Kras mutation can synergistically act with HBx to promote HCC formation and progression remains undefined.
To explore the roles of Kras activation in HCC formation, we utilized the Cre-loxP system to specifically express Kras mutation in hepatocyte and found that hepatocyte-specific Kras activation resulted in HCC formation. Furthermore, HBx co-expression accelerated the formation and malignant progression of the Kras G12D -driven HCC.
RESULTS AND DISCUSSION
Hepatocyte-specific Kras G12D expression causes hepatocellular carcinogenesis in mice To investigate the consequence of hepatocellular Kras G12D expression, we generated Alb-Cre;Kras G12D mice (C57BL6 background) by interbreeding a mouse strain carrying the Kras G12D allele (LSL-Kras G12D ) 26 with a strain expressing an albumin promoter-Cre transgene (Alb-Cre). 27 The LSL-Kras G12D strain carries a point mutation (G12D) in the Kras gene whose expression is blocked by the presence of a loxP-flanked stop codon. After the Cremediated excision of a transcriptional stopper element, Kras G12D allele expressed at the endogenous level. 26 All Alb-Cre;Kras G12D mice were born normally and had no obvious defect in development. At 10 months of age, 46% (6/13) of Alb-Cre;Kras G12D mice exhibited massive nodules with the size ranging from 2-10 mm (Figure 1a-i and 1a-ii; Table 1 (Figure 1b-vi) . In addition, some lesions were accompanied by steatosis and necrosis (Figure 1b-viii) .
Previous studies have reported that the overexpression of Nras or Hras mutation in mouse liver only results in hepatocellular (i) and Alb-Cre;Kras G12D (ii) mice at 11 months of age, with the latter showing macroscopic tumor nodules (arrowhead). H&E staining showed that compared to the normal structure in wild-type control liver (iii), tumor (T) lesion clearly compressed the adjacent normal (N) liver tissue in Alb-Cre;Kras G12D liver (iv). Immunohistochemical analysis showed that AFP (Dako, Carpinteria, CA, USA) was negative in control Kras G12D liver (v), but positive in Alb-Cre;Kras G12D tumor (vi). In contrast, CK19 (Epitomics, Burlingame, CA, USA) marked the biliary epithelium (arrowhead) of control Kras G12D liver (vii) or Alb-Cre;Kras G12D normal region (viii), but did not express in the tumor region of Alb-Cre;Kras G12D liver (viii). The boundary between the tumor (T) and the normal (N) tissue was indicated by a dotted line. 11, 12 Here, we provided the critical in vivo genetic evidence that Kras G12D activation was sufficient for HCC formation and progression. Interestingly, another previously reported Alb-Cre;Kras G12D mouse strain developed intrahepatic cholangiocarcinoma, but not HCC. 13 Given that the same Alb-Cre and Kras G12D strains were used in these two studies, the discordance was likely attributable to the differences in mouse genetic backgrounds. Unlike the previous study, in which the mice were of a mixed background, our Alb-Cre;Kras G12D mice were of a C57BL6 background.
HBx promotes the initiation and progression of Kras G12D -induced HCC In vitro, HBx collaborates with Hras to promote fibroblast cellular transformation. 28, 29 However, no synergistic function between HBx and Nras mutation is found in a mouse model. 11 Next, we tested the functional crosstalk between HBx and Kras in HCC development and progression. HBx knockin transgenic mice were bred with Alb-Cre;Kras G12D mice to generate Alb-Cre;Kras G12D ;HBx double transgenic mice (C57BL6/129s background).
Our previous report showed that 60% of HBx transgenic mice displayed the well-differentiated HCC with an average of 18 months latency. 21 Beginning at 9 months of age, the Kras
G12D
and HBx double transgenic mice became cachectic and presented with abdominal bloating and hemorrhagic ascites (data not shown). The Kaplan-Meier survival curves revealed that the survival of Alb-Cre;Kras G12D ;HBx mice was significantly shorter than that of Alb-Cre;Kras G12D mice (Po0.05, Figure 2a) . As early as 8 months of age, 62.5% (5/8) of Alb-Cre;Kras G12D ;HBx mice exhibited the macroscopic nodules, while no nodule was observed in the age-matched (0/8) Alb-Cre;Kras G12D or (0/6) HBx mice ( Table 1 ). ;HBx ).
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At the age of 10 months, 78% (7/9) of Alb-Cre;Kras G12D ;HBx mice presented tumor nodules compared to 46% (6/13) in AlbCre;Kras G12D mice and 0% (0/6) in HBx mice ( Table 1 ), indicating that HBx co-expression dramatically shortened the tumor latency.
Furthermore, Alb-Cre;Kras G12D ;HBx mice showed more lesions per mouse (Po0.05, Table 2 ) and a larger size per lesion (Po0.05, Table 2 ) when compared to Alb-Cre;Kras G12D mice. In addition, 60% (19/32) of lesions in Alb-Cre;Kras G12D ;HBx livers versus 9% (5/53) in Figure 3 . Molecular alterations in HCCs of Kras G12D and Kras G12D ;HBx transgenic mice. (a) Immunohistochemical analysis of the wild-type Kras G12D liver, the Alb-Cre;Kras G12D and Alb-Cre;Kras G12D ;HBx HCC at 10 months of age with antibodies for p-ERK (Cell Signaling, Danvers, MA, USA), cyclin D1 (Epitomics, Burlingame, CA, USA), b-catenin (Millipore, Billerica, MA, USA), CD44 (BD Biosciences, San Jose, CA, USA), p-Stat3 (Cell Signaling) and E-cadherin (BD Biosciences). Scale bar: 50 mm. (b) Western blot analysis in the wild-type control Kras G12D liver, the AlbCre;Kras G12D and Alb-Cre;Kras G12D ;HBx HCC at 10 months of age. The following antibodies are from Cell Signaling: p-Akt, Akt, p-GSK-3b, GSK-3b, p-Foxo1, Foxo1, p-mTOR, mTOR, p-ERK, ERK, p-p38, p38, p-Stat3, Stat3, p-Smad2/3 and Smad2. The antibody for p53 is from Santa Cruz (Santa Cruz, CA, USA), and the antibodies of cyclin D1 and c-myc are from Epitomics.
Alb-Cre;Kras G12D livers were identified as the poorly differentiated HCC (Po0.01, Figure 2b ). Taken together, the above data suggest that HBx co-expression dramatically promotes the initiation and progression of Kras G12D -induced HCC.
Kras G12D and HBx expression increases hepatocellular proliferation
We next investigated whether the HCC induced by Kras G12D and HBx expression was due to the enhanced cellular proliferation. BrdU-labeling results showed that BrdU-positive cells were scarce in the control livers, but increased in HCC lesions of AlbCre;Kras G12D livers (Po0.01, Figures 2c and d) . Strikingly, the BrdU-positive cells in Kras G12D and HBx double HCCs further increased by 2.2 folds than that in Kras G12D HCCs (Po0.01, Figures  2c and d) . We also tested whether the enhanced proliferation index was accompanied by the abnormal apoptosis. Immunostaining analysis of cleaved caspase-3 revealed that there was no significant difference among wild type control, Alb-Cre;Kras
G12D
and Alb-Cre;Kras G12D ;HBx HCCs (Figure 2c ). These results demonstrated that the boosted hepatocellular proliferation caused by the synergistic effect between Kras mutation and HBx may be responsible for the accelerated HCC formation in Kras G12D and HBx double transgenic mice. Kras  G12D and Kras G12D ;HBx transgenic mice We next explored the molecular alterations in the HCCs induced by Kras G12D and HBx expression. Overwhelming evidence has shown that Ras exerts various cellular activities through regulating its downstream pathways such as Akt, MAPK, Stat3 and p53. 8 All of them are correlated with HCC malignant progression and poor prognosis in the clinical studies. [30] [31] [32] On the other hand, HBx can not only directly stimulate Ras activity 33 but also affect some Rasregulated pathways such as Akt, MAPK and p53. [34] [35] [36] [37] [38] In addition, HBx can regulate b-catenin, CD44, TANK-binding kinase-1 and E-cadherin, all of which are involved in HCC formation or progression. [39] [40] [41] [42] We found that Akt, MAPK, Stat3 and TGF-b pathways were activated in the Kras G12D -driven HCCs, as supported by the upregulation of p-Akt, p-GSK-3b, p-Foxo1, p-ERK, p-p38, p-Stat3, p-Smad2/3, cyclin D1 and c-myc, while p53 expression was decreased (Figures 3a and b) . The deregulation of Akt, MAPK, p53 and TGF-b pathways was significantly enhanced in Kras G12D and HBx double transgenic HCCs (Figures 3a and b) , indicating that HBx and Kras mutation might have a synergistic function in regulating these pathways. We also found that the increased expressions of b-catenin, CD44 and TANK-binding kinase-1 as well as the decreased expression of E-cadherin were only exhibited in HCCs of Kras G12D and HBx double transgenic but not Kras G12D mice (Figures 3a and b) . Taken together, the molecular alterations further confirm the synergistic function of Kras G12D and HBx expression in hepatocelluar carcinogenesis. In summary, we provided the first in vivo genetic evidence that hepatocellular Kras G12D expression induced HCC and demonstrated that Kras G12D and HBx synergistically promoted the initiation and progression of HCC. Currently, many of the small molecular inhibitors specific for PI3K/Akt, ERK, p38 and Stat3 pathways are being evaluated in clinical trials. [43] [44] [45] The novel genetic mouse models of HCC created in this study will be valuable for evaluating the efficacy of drugs especially targeting these pathways.
Molecular alterations in the HCCs of

